$15

Psilocybin Therapy and Mental Health Care in Oregon

Actions and Detail Panel

$15

Event Information

Share this event

Date and time

Location

Location

Online event

Event description
Friday Lunchtime Panel Discussion

About this event

Online Webinar: Psilocybin Therapy and Mental Health Care in Oregon: What is Happening and Where do we Need to Go From Here?

Oregon Voters have recently approved a measure that will pave the way for the legal administration of psilocybin by state credentialed providers to begin in 2023. This groundbreaking development places therapists in the unique position of potentially being some of the first to have an avenue to legally integrate psychedelic-assisted therapy into their practices. While psychedelic-assisted therapy research studies' results are promising and an FDA Approval of a psychedelic for psychological treatment may occur in the next few years, the Oregon Psilocybin initiative represents a unique pathway to public access. Where does the psychotherapist sit in this conversation? In this panel discussion, leading advocates, psychedelic therapy researchers, and psychedelic therapist training providers will elaborate on the implications during a moderated panel discussion and answer audience questions. Presenters will give an update on the status of the Oregon Psilocybin initiative, particularly as it relates to the training of facilitators, and will describe ways local therapists can get training in the practice of psilocybin-assisted therapy.

This webinar is a fundraiser for a clinical trial of MDMA-assisted psychotherapy for social anxiety disorder that Portland Psychotherapy investigators are preparing. All proceeds will go to fund this clinical trial.

AUDIENCE: The audience is aimed at mental health and healthcare professionals considering involvement with psilocybin services in Oregon

REGISTRATION: Registration is online. This event will be available as a recording on YouTube for ticket holders after the event.

Scholarships: We reserve a number of partial scholarships for potential attendees who could not otherwise afford to come. We give particular priority given to those who would add diverse and underrepresented voices to our field. To submit an application, please click here.

 Moderator:

Brian Pilecki, Ph.D. is a clinical psychologist at Portland Psychotherapy that specializes in the treatment of anxiety disorders (OCD, generalized anxiety, social anxiety, panic disorder), trauma and PTSD, and matters related to the use of psychedelics. He completed a post-doctoral fellowship at The Warren Alpert Medical School of Brown University and practices from an orientation based in Acceptance and Commitment Therapy (ACT). Brian also has extensive experience in the areas of mindfulness and meditation and incorporates them into his therapy with clients. He is an active researcher and has published on topics such as anxiety disorders, mindfulness, and the relationship between theory and practice in psychotherapy. At Portland Psychotherapy, Brian is also involved in research in the use of psychedelics for the treatment of mental health problems.

Panelists:

Ingmar Gorman, PhD. is a co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike. Dr. Gorman received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University. He simultaneously served as site co-principal investigator on an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist on the same study, as well as another FDA approved clinical trial of psilocybin for treatment-resistant depression. Dr. Gorman has published on the topics of classic psychedelics, ketamine, MDMA, and Psychedelic Harm Reduction and Integration.

Kelly Sykes, PhD. is a child forensic psychologist and maintains a private practice in Brooklyn, New York. She works primarily with court-referred families as a custody evaluator, parenting or family coordinator, or therapeutic supervisor. She also provides expert consultation and testimony in matters that concern parent-child contact problems, child sexual abuse evaluations, trauma & parenting, and adoption & termination of parental rights. Her work is heavily influenced by psychoanalysis and attachment theory. Kelly’s interest in psychedelic integration therapy evolved from years of working with court-referred parents with histories of complex trauma, persistent mood disorders, and substance abuse problems. Noting that for some, talk therapies helped with insight but failed to inhibit endangering behavior or led to meaningful change such that they could parent their children. This sparked her interest in learning more about the role the brain plays in the chronicity of certain psychological conditions and the research on psychedelic treatments

Alan Davis, PhD. is an Assistant Professor of Social Work at Ohio State University and Adjunct Assistant Professor in the Center for Psychedelic and Consciousness Research at Johns Hopkins University. Dr. Davis’s clinical experience includes working with people diagnosed with trauma-based psychological problems and includes providing evidenced-based treatments such as motivational interviewing, acceptance and commitment therapy, and psilocybin-assisted psychotherapy. His research interests focus on helping those suffering with substance use and mental health problems and developing ways to conceptualize substance use and mental health problems through a strengths-based approach. He recently completed a clinical trial of psilocybin therapy for depression and current trials exploring psychedelic treatment for patients with co-occurring alcohol use disorder and depression and patients with anorexia. He examines topics related to naturalistic psychedelic use among several populations including people of color who have experienced racial trauma, Spanish-speaking people, and people who use novel psychedelics such as 5-MeO-DMT.

Aja Molinar is a graduate student in psychology at the New School for Social Research, where she is a member of the Psychopathology Lab. Aja is also a member of the Portland Psychedelics Virtual Research Lab led by Dr. Jason Luoma and Dr. Brian Pilecki. She is interested in psychedelic science, in addition to research on boredom and depression. Within the Psychopathology Lab, she is also part of a team designing a protocol to measure clinical outcomes for ketamine-assisted psychotherapy. Aja has also assisted in writing a peer-reviewed article with Dr. Ingmar Gorman and Dr. Elizabeth Nielson on psychedelic harm reduction and integration.

Sam Chapman is the Executive Director for the Healing Advocacy Fund, a nonprofit organization supporting the implementation of Measure 109 in Oregon with education and advocacy. Sam has over a decade of experience in advocating for progressive drug policy reforms at the local, state, and national level. His previous experience includes consulting for statewide political campaigns, assisting local governments in writing rules and regulations, crafting and advocating for equitable access to emerging healthcare treatment options, and identifying new opportunities within emerging industries. In 2013 Sam co-authored House Bill 3460, the Oregon law that legalized medical marijuana dispensaries. Most recently, Sam served as the Campaign Manager for Measure 109 in Oregon, the law that legalized the first-ever psilocybin therapy program in the country. Sam has been a resident of Oregon for 25 years. He holds a bachelor's degree from the University of Oregon in Philosophy and Political Science.

Refund/cancellation policy:

We charge a $10 administration fee for cancellations.

Special Accommodations:

Please contact us if you need accommodations to enable you to fully participate in the workshop. We will work with you and do our best to find a way to ensure your participation.

Get Our Newsletter

To stay up to date on all the different workshops we offer, you can join our newsletter here.


		Psilocybin Therapy and Mental Health Care in Oregon image

		Psilocybin Therapy and Mental Health Care in Oregon image

		Psilocybin Therapy and Mental Health Care in Oregon image

		Psilocybin Therapy and Mental Health Care in Oregon image

		Psilocybin Therapy and Mental Health Care in Oregon image

		Psilocybin Therapy and Mental Health Care in Oregon image

		Psilocybin Therapy and Mental Health Care in Oregon image

		Psilocybin Therapy and Mental Health Care in Oregon image
Share with friends

Date and time

Location

Online event

Save This Event

Event Saved